Literature DB >> 8629830

The adjuvant therapy of pemphigus. An update.

J C Bystryn1, N M Steinman.   

Abstract

Systemic corticosteroids remain the mainstay of therapy for pemphigus. Their use has transformed what was almost invariably a fatal illness into one whose mortality is now below 10%. Unfortunately, the high doses and prolonged administration of corticosteroids that are often needed to control the disease result in numerous side effects, many of which are serious. Most patients who die of pemphigus at present die of complications of therapy. This has led to a continued search for alternative treatments that might reduce the need for steroids. Those treatments now in use are usually given in combination with steroids and, for that reason, are referred to as adjuvant therapies. This article summarizes progress in the adjuvant therapy of pemphigus since the last review of this subject 10 years ago.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8629830

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  27 in total

1.  Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

Authors:  Rosangela Soares Chriguer; Ana Maria Roselino; Margaret de Castro
Journal:  J Clin Immunol       Date:  2012-03-10       Impact factor: 8.317

2.  [Therapy resistant pemphigus vulgaris. Combination therapy with methylprednisolone and doxycycline].

Authors:  T Assmann; R Voss; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

3.  [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].

Authors:  C Mühlhoff; M Megahed
Journal:  Hautarzt       Date:  2007-11       Impact factor: 0.751

Review 4.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

5.  [Pemphigus vulgaris. Therapy with cyclophosphamide].

Authors:  L Vanstreels; A Alkhateeb; M Megahed
Journal:  Hautarzt       Date:  2013-05       Impact factor: 0.751

6.  Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study.

Authors:  K Kridin; S Zelber-Sagi; D Comaneshter; A D Cohen
Journal:  Epidemiol Psychiatr Sci       Date:  2017-09-25       Impact factor: 6.892

7.  RECENT TRENDS IN THE MANAGEMENT OF PEMPHIGUS VULGARIS.

Authors:  P K Kar
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 8.  Novel therapies for pemphigus vulgaris: an overview.

Authors:  Oliver A Perez; Timothy Patton
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  [Gold. Effective therapy for mucosal lesions of pemphigus vulgaris].

Authors:  D Lange; F Meiss; E Fiedler; K Treiber; W C Marsch; M Fischer
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

Review 10.  Pemphigus group: overview, epidemiology, mortality, and comorbidities.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.